Amgen Inc (AMGN) 162.24 $AMGN
Final Glance: Biotechnology companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.95%
Comtex SmarTrend(R) - Tue Nov 18, 3:50PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $158.37 to a high of $162.39. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $162.35 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.24 (+3.10)
Amgen Rises 1.95% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Nov 18, 3:49PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $158.37 to a high of $162.39. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $162.35 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.24 (+3.10)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), MRK: 59.89 (+0.43), AMGN: 162.24 (+3.10), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27), CELG: 106.78 (+2.42)
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
PR Newswire - Tue Nov 18, 3:00PM CST
Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. Data from one of the long-term pooled analyses showed that evolocumab significantly reduced lipoprotein(a) (Lp(a)) over 64 weeks. Data from a separate long-term, 52-week pooled analysis showed that adverse events (AEs) were overall balanced between patients who achieved LDL-C levels of <40 mg/dL and those who achieved LDL-C levels of >40 mg/dL. Another pooled analysis showed the two dosing regimens of evolocumab were clinically equivalent. These evolocumab data were included as part of the 13 presentations showcased at the American Heart Association (AHA) Scientific Sessions 2014.
AMGN: 162.24 (+3.10)
Midday Glance: Biotechnology companies
AP - Tue Nov 18, 12:24PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Early Glance: Biotechnology companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.59 (+0.27), MRK: 59.89 (+0.43), AMGN: 162.24 (+3.10), REGN: 413.22 (+13.57)
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 14.67 (+0.21), BAX: 72.58 (+0.58), AMGN: 162.24 (+3.10), LLY: 67.78 (+0.49), BMY: 58.70 (+0.27), SVA: 5.05 (-0.01)
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.97%
Comtex SmarTrend(R) - Fri Nov 14, 3:45PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.62 to a high of $161.28. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $159.58 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 162.24 (+3.10)
After Yesterday's Decline of 1.97%, Amgen Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 3:44PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.62 to a high of $161.28. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $159.58 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 162.24 (+3.10)
Amgen To Present At The Jefferies Global Healthcare Conference
PR Newswire - Fri Nov 14, 3:15PM CST
Amgen (NASDAQ: AMGN) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014, in London, beginning at 8:40 a.m. GMT. Arvind Sood, vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 162.24 (+3.10)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 305.56 (+3.14), VRTX: 111.04 (-0.58), GILD: 103.71 (+3.27), ALXN: 192.37 (+5.59), AMGN: 162.24 (+3.10), IBB: 295.25 (+6.41), REGN: 413.22 (+13.57), CELG: 106.78 (+2.42)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), SNY: 48.36 (+0.82), REGN: 413.22 (+13.57)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.83 (+0.53), AZN: 73.98 (+1.48), AMGN: 162.24 (+3.10), AMAG: 35.34 (+0.58)
Final Glance: Biotechnology companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.95%
Comtex SmarTrend(R) - Tue Nov 18, 3:50PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $158.37 to a high of $162.39. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $162.35 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.24 (+3.10)
Amgen Rises 1.95% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Nov 18, 3:49PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $158.37 to a high of $162.39. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $162.35 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.24 (+3.10)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), MRK: 59.89 (+0.43), AMGN: 162.24 (+3.10), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27), CELG: 106.78 (+2.42)
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
PR Newswire - Tue Nov 18, 3:00PM CST
Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. Data from one of the long-term pooled analyses showed that evolocumab significantly reduced lipoprotein(a) (Lp(a)) over 64 weeks. Data from a separate long-term, 52-week pooled analysis showed that adverse events (AEs) were overall balanced between patients who achieved LDL-C levels of <40 mg/dL and those who achieved LDL-C levels of >40 mg/dL. Another pooled analysis showed the two dosing regimens of evolocumab were clinically equivalent. These evolocumab data were included as part of the 13 presentations showcased at the American Heart Association (AHA) Scientific Sessions 2014.
AMGN: 162.24 (+3.10)
Midday Glance: Biotechnology companies
AP - Tue Nov 18, 12:24PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Early Glance: Biotechnology companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.59 (+0.27), MRK: 59.89 (+0.43), AMGN: 162.24 (+3.10), REGN: 413.22 (+13.57)
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 14.67 (+0.21), BAX: 72.58 (+0.58), AMGN: 162.24 (+3.10), LLY: 67.78 (+0.49), BMY: 58.70 (+0.27), SVA: 5.05 (-0.01)
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.97%
Comtex SmarTrend(R) - Fri Nov 14, 3:45PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.62 to a high of $161.28. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $159.58 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 162.24 (+3.10)
After Yesterday's Decline of 1.97%, Amgen Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 3:44PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.62 to a high of $161.28. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $159.58 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 162.24 (+3.10)
Amgen To Present At The Jefferies Global Healthcare Conference
PR Newswire - Fri Nov 14, 3:15PM CST
Amgen (NASDAQ: AMGN) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014, in London, beginning at 8:40 a.m. GMT. Arvind Sood, vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 162.24 (+3.10)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 305.56 (+3.14), VRTX: 111.04 (-0.58), GILD: 103.71 (+3.27), ALXN: 192.37 (+5.59), AMGN: 162.24 (+3.10), IBB: 295.25 (+6.41), REGN: 413.22 (+13.57), CELG: 106.78 (+2.42)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), SNY: 48.36 (+0.82), REGN: 413.22 (+13.57)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.83 (+0.53), AZN: 73.98 (+1.48), AMGN: 162.24 (+3.10), AMAG: 35.34 (+0.58)
